Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase

Xenobiotica

Volumn 46, Issue 7, 2016, Pages 579-590

  Isobe, Tomoyuki ^a,b   Ohta, Masayuki ^a   Kaneko, Yoshio ^a   Kawai, Hiroyuki ^a  

^a KOWA COMPANY LTD   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Glaucoma; hepatocyte; instillation; noncytochrome P 450; pharmacokinetics; ROCK; S9

Indexed keywords

ALDEHYDE OXIDASE; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RECOMBINANT ENZYME; RIPASUDIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEAGLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; ENZYME KINETICS; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; LIVER CELL; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE; METABOLIC STABILITY; METABOLISM; METABOLITE; NEW ZEALAND RABBIT; NONHUMAN; RAT; SPECIES DIFFERENCE;

EID: 84950131566     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1096981     Document Type: Article

References (44)

1. Acheampong AA, Chien DS, Lam S, et al. (1996). Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 26: 1035-55
2. Akabane T, Tanaka K, Irie M, et al. (2011). Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41: 372-84
3. Akabane T, Gerst N, Naritomi Y, et al. (2012). A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes. Drug Metab Pharmacokinet 27: 181-91
4. Bahrami H. (2006). Causal inference in primary open angle glaucoma: specific discussion on intraocular pressure. Ophthalmic Epidemiol 13: 283-9
5. Beedham C. (1985). Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 16: 119-56
6. Beedham C. (1987). Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 24: 85-127
7. Beedham C, Miceli JJ, Obach RS. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23: 229-32
8. Diamond S, Boer J, Maduskuie TP Jr, et al. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38: 1277-85
9. Dittrich CH, Greim G, Borner M, et al. (2002). Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38: 1072-80
10. Edeki TI, He H, Wood AJ. (1995). Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 274: 1611-13
11. Garattini E, Fratelli M, Terao M. (2008). Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 65: 1019-48
12. Garattini E, Terao M. (2012). The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8: 487-503
13. Hall A. (2005). Rho GTPases and the control of cell behaviour. Biochem Soc Trans 33: 891-5
14. Hutzler JM, Yang YS, Albaugh D, et al. (2012). Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 40: 267-75
15. Hutzler JM, Yang YS, Brown C, et al. (2014). Aldehyde oxidase activity in donor-matched fresh and cryopreserved human hepatocytes and assessment of variability in 75 donors. Drug Metab Dispos 42: 1090-7
16. Imaoka S, Yamada T, Hiroi T, et al. (1996). Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51: 1041-50
17. Inoue T, Tanihara H. (2013). Rho-Associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res 37: 1-12
18. Isobe T, Mizuno K, Kaneko Y, et al. (2014). Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res 39: 813-22
19. Itoh K, Yamamura M, Takasaki W, et al. (2006). Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharm Drug Dispos 27: 133-9
20. Johns DG. (1967). Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 46: 1492-505
21. Kitamura S, Sugihara K, Nakatani K, et al. (1999). Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 48: 607-11
22. Kitamura S, Sugihara K, Ohta S. (2006). Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21: 83-98
23. Kurosaki M, Demontis S, Barzago MM, et al. (1999). Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone. Biochem J 341: 71-80
24. Kurosaki M, Bolis M, Fratelli M, et al. (2013). Structure and evolution of vertebrate aldehyde oxidases: from gene duplication to gene suppression. Cell Mol Life Sci 70: 1807-30
25. Lake BG, Ball SE, Kao J, et al. (2002). Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32: 835-47
26. Massey V, Komai H, Palmer G, Elion GB. (1970). On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem 245: 2837-44
27. Moriwaki Y, Yamamoto T, Takahashi S, et al. (2001). Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol Histopathol 16: 745-53
28. Moriyasu A, Sugihara K, Nakatani K, et al. (2006). In vivo-in vitro relationship of methotrexate 7-hydroxylation by aldehyde oxidase in four different strain rats. Drug Metab Pharmacokinet 21: 485-91
29. Nakashima M, Uematsu T, Kanemaru M. (1992). Phase I study of AT-877 (fasudil hydrochloride) in healthy subjects. Single and multiple administration. Jpn Pharmacol Ther 20: S1559-85
30. Nishimura M, Naito S. (2006). Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21: 357-74
31. Obach RS. (2004a). Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32: 89-97
32. Obach RS, Huynh P, Allen MC, Beedham C. (2004b). Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44: 7-19
33. Olson MF. (2008). Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20: 242-8
34. Pryde DC, Dalvie D, Hu Q, et al. (2010). Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53: 8441-60
35. Rao VP, Epstein DL. (2007). Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Biodrugs 21: 167-77
36. Riento K, Ridley AJ. (2003). Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446-56
37. Sahi J, Khan KK, Black CB. (2008). Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab Lett 2: 176-83
38. Shimokawa H, Takeshita A. (2005). Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-75
39. Tanihara H, Inoue T, Yamamoto T, et al. (2013a). Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol 131: 1288-95
40. Tanihara H, Inoue T, Yamamoto T, et al. (2013b). Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-Angle glaucoma and ocular hypertension. Am J Ophthalmol 156: 731-6
41. Tanihara H, Inoue T, Yamamoto T, et al. (2015a). Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol 133: 755-61
42. Tanihara H, Inoue T, Yamamoto T, et al. (2015b). One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-Angle glaucoma and ocular hypertension. Acta Ophthalmol. [Epub head of print]. doi: 10.1111/aos.12829
43. Zhang X, Liu HH, Weller P, et al. (2011). In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 11: 15-24
44. Zientek M, Jiang Y, Youdim K, Obach RS. (2010). In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38: 1322-7